Acromegaly is a rare but severe condition caused by excessive growth hormone in the blood. Growth hormone is released into the bloodstream by the pituitary gland. The blood carries growth hormone to other parts of the body, where it has specific effects.
Acromegaly is caused in the majority of patients, by growth hormone-producing pituitary adenomas. Based on the type of adenomas, Acromegaly is classified into two groups, i.e., Macroadenomas and Microadenomas.
Acromegaly Signs & Symptoms
A common sign of acromegaly is enlarged hands and feet. Acromegaly can also cause gradual changes in your face's shape, such as a protruding lower jaw and brow bone, thickened lips, and wider spacing between your teeth. Acromegaly is a rare condition and each year, about three new cases occur for every million people.
Overall, acromegaly signs and symptoms tend to vary from person to person, and may include oily and thickened skin, excessive sweating and body odor, fatigue and joint weakness, husky voice, and sinuses, severe snoring, vision problems, menstrual cycle irregularities in women, loss of interest in sex.
Acromegaly Epidemiology Insights:
As per DelveInsight analysis, the total number of prevalent cases of acromegaly is 64,508, in 7MM during 2017, and a diagnosed patient pool is estimated, 49,814 patients.
The Acromegaly prevalent population was estimated to be 28,671, and 10,690 cases in the United States, and Japan respectively, during 2017. The diagnosed cases of Acromegaly supported forms of Adenomas were 18,349 macroadenomas and 4,587 microadenomas in 2017, in the United States.
Acromegaly Treatment Options
The purpose of treatment is to lower growth hormone. Treatment could be surgery, pituitary irradiation, medication.
Therapies that can be used in the Acromegaly treatment may include somatostatin analogs, dopamine agonists, and growth hormone antagonists. Radiation treatment often lowers levels of other pituitary hormones, too- not just the growth of hormones.
Types of radiation therapy are:
Conventional radiation therapy
Stereotactic radiosurgery
Acromegaly Market Landscape
The Acromegaly market is predicted to grow by factors, like an increase within the prevalent pool, expected entry of emerging therapies with novel targets and engaging pricing, expected launch of Octreotide capsules, and more penetration within the 7MM markets.
The rapid change in the Acromegaly market is basically attributed to the launch of Mycapssa and CAM2029, along with the sturdy clinical pipeline and the upcoming launch of emerging therapies in the forecasted period 2017–2030.
The emerging therapies for the treatment of acromegaly which are expected to launch in the forecasted period 2017–2030 include Octreotide Capsules (Mycapssa) by Chiasma Pharma, IONIS-GHR-LRx by Celgene Corporation, Atesidorsen by Antisense Therapeutics, and others.
Sign in to leave a comment.